

## **Abuse Liability of Drugs**

**Mission:** The Committee on Abuse Liability of Drugs (CALD) shall focus on issues related to education, evaluation and testing of compounds with abuse liability. The CALD shall provide an impartial forum for promoting discussions and opinions of issues related to abuse liability assessment in animals and humans, and educating clinicians, government officials and the lay community in all facets of drug abuse, including risk management. In particular, the committee shall seek to encourage communication between members of government, industry and academia that require, can provide, or have an interest in abuse liability issues.

**Committee Members:** Members of the Committee and its Chair are appointed by the President-Elect of CPDD for 3-year terms. Terms begin and end immediately after the Annual Meeting. Membership shall usually include representation of all of the following: clinical researcher; preclinical researcher; and representatives of FDA, DEA, NIDA and the pharmaceutical industry.

**Committee Operations:** The Committee usually meets at the Annual Meeting of CPDD and conducts business through e-mail otherwise. The Committee may also convene or support satellite meetings to address specific topics.

The Committee typically presents the following reports to the CPDD Board:

- A report is prepared for the mid-year meeting of the Board of Directors.
- A report to the full Board at the Annual Meeting in June. This report is usually presented by the Committee Chair.